RECALL RECORD — CLASS IIRecall closedF-1756-2018/FDA enforcement

Genestra Brand Afa-gen Capsule 15 mg Niacin/ Capsule 300 mg Blue Green Algae / Capsule 2…

What you need to know

Class II
  • What happened

    Microcystins level found to be above the specification limit of NMT1 ppm as per Raw Material Specification.

  • Health risk

    The product may cause temporary or medically reversible health consequences, or the probability of serious harm is remote. A safety issue that does not fit the standard pathogen, allergen, chemical or quality categories.

  • Action required

    Stop taking the supplement. Check the lot and UPC codes below, then return it to the retailer or contact the manufacturer about a refund. Seek medical advice if you have concerns about exposure.

Recall closed · classified by the FDADistribution not listedMore supplements

Advertisement

Ad

Know someone who bought this?

A quick share can keep a pantry check from becoming a missed warning.

Match before you discard

Product identification

Source: FDA FOOD

Brand nameSeroyal International, a Division of Atrium Innovations
Recalling firmSeroyal International, a Division of Atrium InnovationsRichmond Hill, Ontario, Canada
UPC / barcodesNo UPC listed in the FDA enforcement record.
Lot / date codes
  • Lot # 6E436-0
  • Product Code # 07596
  • Expiry Date: 09/2018
Distribution area

Product was distributed throughout the United States and Canada (see attached document for list of Canadian consignees).

United States, Canada

Quantity affected4, 226 bottles (1691 Canada and 2535 USA)
Recall initiationFDA report date: August 15, 2018
FDA recall numberF-1756-2018

Beyond the headline

The recall, in context

Seroyal International, a Division of Atrium Innovations initiated this supplements recall on July 27, 2018. The FDA enforcement report states: Microcystins level found to be above the specification limit of NMT1 ppm as per Raw Material Specification. The FDA report lists distribution as: Product was distributed throughout the United States and Canada (see attached document for list of Canadian consignees).

The FDA enforcement report describes the reason as: Microcystins level found to be above the specification limit of NMT1 ppm as per Raw Material Specification.

Genestra Brand Afa-gen Capsule 15 mg Niacin/ Capsule 300 mg Blue Green Algae / Capsule 2… was made or distributed by Seroyal International, a Division of Atrium Innovations in Richmond Hill, Ontario, Canada. This page reflects FDA report F-1756-2018, dated August 15, 2018.

Why this is a Class II recall

Class II means the product may cause temporary or medically reversible health consequences, or the probability of serious harm is remote. In this recall, a safety issue that does not fit the standard pathogen, allergen, chemical or quality categories.

FDA definition

The product may cause temporary or medically reversible health consequences, or the probability of serious harm is remote.

What to do now

  1. 1

    Stop using it

    Do not eat, drink or take the affected product.

  2. 2

    Check the codes

    Compare the lot and date codes against the table above.

  3. 3

    Return or discard

    Contact the retailer or recalling firm about a refund, and dispose of the product safely.

Consumer safety guide

Product safety recall

Symptoms to watch for

The official enforcement report describes the specific risk. Follow the recall notice, check the product codes and do not use a product that may be affected.

Higher-risk groups

Children, pregnant people, older adults and people with weakened immune systems should take extra care when a product's safety is uncertain.

What to do now

  1. 1Stop using or eating the product and keep it away from children and pets.
  2. 2Check the UPC and lot/date codes on this page and follow the official recall notice for disposal or return.
  3. 3Seek medical advice if anyone develops severe or worrying symptoms after exposure.

Read the official source record for the specific hazard and instructions.

This is general consumer safety information, not medical advice or a diagnosis. Follow the official recall notice and contact a healthcare professional if you have concerns about exposure or symptoms.

Frequently asked

Questions about this recall

What is the Genestra Brand Afa-gen Capsule 15 mg Niacin/ Capsule 300 mg Blue Green Algae / Capsule 2… recall?

Seroyal International, a Division of Atrium Innovations recalled Genestra Brand Afa-gen Capsule 15 mg Niacin/ Capsule 300 mg Blue Green Algae / Capsule 2… in an FDA Class II enforcement action reported as F-1756-2018. Microcystins level found to be above the specification limit of NMT1 ppm as per Raw Material Specification.

What should I do if I bought this product?

Stop taking the supplement. Check the lot and UPC codes below, then return it to the retailer or contact the manufacturer about a refund. Seek medical advice if you have concerns about exposure. Stop using or eating the product and keep it away from children and pets. Check the UPC and lot/date codes on this page and follow the official recall notice for disposal or return. Seek medical advice if anyone develops severe or worrying symptoms after exposure.

Is the Seroyal International, a Division of Atrium Innovations recall still active?

The FDA lists this recall as recall closed. It remains relevant if you still have the affected product or need to identify a historical recall.

Where can I verify this recall?

This page is normalized from the openFDA enforcement record F-1756-2018. You can verify it directly using the official source link on this page. VerifyRecall updates its index from public FDA enforcement data and does not replace advice from the FDA, the recalling firm or a healthcare professional.

Verify before you act.

VerifyRecall is independent and not affiliated with the FDA. Always confirm the latest status on the official source record.

Official source

Related alerts

Recent Other safety concern recalls

All alerts

Record last synced from official openFDA enforcement data on November 14, 2026. Source record: official FDA notice.